In this post I will continue to highlight AACR abstracts relevant to the small-cap biotech companies that covered here at BiotechDueDiligence and/or may be of interest to readers.
Full coverage:
Introduction
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Preview Part 5 (TKMR, EXEL, PCYC, IMMU, VRTX)
Full coverage:
Introduction
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Preview Part 5 (TKMR, EXEL, PCYC, IMMU, VRTX)
Abstract numbers link you to fulltext c/o AACR.
CUDC-101, a hybrid molecular targeted agent, reverses multiple mechanisms of drug resistance (Abstract 976) Curis $CRIS
Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119 (Abstract 1891) Infinity Pharma
There don't appear to be any presentations on INFI's lead PI3K inhibitor IPI-145, but here is another molecule in their preclinical pipeline. See the links to preview parts 1 and 2 for abstracts relevant to Infinity's HSP90 inhibitor retaspamycin HCl.
Antisense oligonucleotide depletion of the mitotic kinesin Eg5 by direct delivery to the brain could be a useful strategy for treating glioma tumors (Abstract 3302) Isis Pharmaceuticals $ISIS
Also relevant to the SMA antisense program partnered with Biogen BIIB which involves direct intrathecal route of administration
Potent in vivo pharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models (Abstract LB-317) Isis Pharmaceuticals $ISIS, partnered with AstraZeneca $AZN
Characterization of the response of human T cells to an agonist human anti-CD27 mAb (Abstract 1239) Celldex Therapeutics $CLDX
Carfilzomib demonstrates broad antitumor activity in preclinical lung cancer models (Abstract 1022) Onyx Pharmaceuticals $ONXX and Ligand Pharmaceuticals $LGND
The bruton’s tyrosine kinase inhibitor ibrutinib synergized with the proteasome inhibitor carfilzomib and overcame immunoproteasome-mediated carfilzomib resistance in mantle cell lymphoma (Abstract 2432) Onyx Pharmaceuticals $ONXX, Ligand Pharmaceuticals $LGND, and Pharmacyclics $PCYC
Note there are a few more carfilzomib abstracts, but these two caught my eye
CUDC-101, a hybrid molecular targeted agent, reverses multiple mechanisms of drug resistance (Abstract 976) Curis $CRIS
Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119 (Abstract 1891) Infinity Pharma
There don't appear to be any presentations on INFI's lead PI3K inhibitor IPI-145, but here is another molecule in their preclinical pipeline. See the links to preview parts 1 and 2 for abstracts relevant to Infinity's HSP90 inhibitor retaspamycin HCl.
Antisense oligonucleotide depletion of the mitotic kinesin Eg5 by direct delivery to the brain could be a useful strategy for treating glioma tumors (Abstract 3302) Isis Pharmaceuticals $ISIS
Also relevant to the SMA antisense program partnered with Biogen BIIB which involves direct intrathecal route of administration
Potent in vivo pharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models (Abstract LB-317) Isis Pharmaceuticals $ISIS, partnered with AstraZeneca $AZN
Characterization of the response of human T cells to an agonist human anti-CD27 mAb (Abstract 1239) Celldex Therapeutics $CLDX
Carfilzomib demonstrates broad antitumor activity in preclinical lung cancer models (Abstract 1022) Onyx Pharmaceuticals $ONXX and Ligand Pharmaceuticals $LGND
The bruton’s tyrosine kinase inhibitor ibrutinib synergized with the proteasome inhibitor carfilzomib and overcame immunoproteasome-mediated carfilzomib resistance in mantle cell lymphoma (Abstract 2432) Onyx Pharmaceuticals $ONXX, Ligand Pharmaceuticals $LGND, and Pharmacyclics $PCYC
Note there are a few more carfilzomib abstracts, but these two caught my eye
RSS Feed
